A Phase 3 interventional study of Ibrutinib and Venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 88 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 8 open to participants now, 28 under way, 4 of them phase 3. ibrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 15th largest by enrollment, is one of 8 that started in 2018, is one of 14 in phase 3, reaches primary completion later than 7 of the 27 other live ones, and was the 58th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →8 of the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–80
Gruppo Italiano Malattie EMatologiche dell'Adulto · Sites in Italy
Ages 18+
Paolo Ghia · Sites in Italy
Ages 18–65
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18–75
Jeanette Lundin · Sites in Norway, Sweden
Ages 18+
By country, each count listing its studies:
ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 51 · Phase 3 15 · Phase 4 1
First in 2010; this study’s year is marked. 8 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 211 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 44 across the 83 interventional studies. Of the 44 that completed or were terminated, 26 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 83 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 933 studies on the registry; 77 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
26 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Johnson & Johnson: 3 open now, 7 under way, 2 of them phase 3. Of 16 finished, 3 (19%) have results posted.
Among the 26 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Johnson & Johnson, this one is the 5th largest by enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2018, is one of 4 in phase 3, and was the 14th registered.
Johnson & Johnson’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 1990.
6 of the studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT03513562Ohio State University Comprehensive Cancer CenterVenetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations | 2026-12-31 |
| NCT03153202Joshua BrodyStudy to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) | 2027-04 |
| NCT03960840Novartis PharmaceuticalsPhase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL | 2027-06-30 |
| NCT02756897M.D. Anderson Cancer CenterVenetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia | 2027-07-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Among Johnson & Johnson’s 26 in Leukemia, Lymphocytic, Chronic, B-Cell:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzumab plus chlorambucil (G-Clb) as assessed by an Independent Review Committee (IRC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adult participants who are: (a) greater than or equal to (>=) 65 years old or, (b) 18 to 64 years old and have at least 1 of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will initially receive ibrutinib (420 mg \[milligrams\]/day) for 3 cycles. Venetoclax dose ramp up (from 20 to 400 mg over 5 weeks) will begin at Cycle 4 and the combination of ibrutinib and venetoclax will be given for 12 cycles (each cycle is equivalent to 28 days). Participants who subsequently develop progressive disease may enter to Subsequent Therapy Phase to receive single-agent ibrutinib until disease progression or unacceptable toxicity.
Drug: Ibrutinib · Drug: Venetoclax · Drug: Ibrutinib (as Subsequent Therapy)
Participants will receive chlorambucil and obinutuzumab (G-Clb) for 6 cycles. Participants will receive obinutuzumab, 1000 mg intravenously (IV) on Days 1, 8 and 15 of Cycle 1, and on Day 1 of Cycles 2 to 6 and chlorambucil 0.5 milligrams per kilogram (mg/kg) body weight, on Days 1 and 15 of Cycles 1 to 6. Participants who subsequently develop progressive disease may enter to Subsequent Therapy Phase to receive single-agent ibrutinib until disease progression or unacceptable toxicity.
Drug: Chlorambucil · Drug: Obinutuzumab · Drug: Ibrutinib (as Subsequent Therapy)
Participants will receive ibrutinib 420 mg orally once daily up to 15 cycles.
Participants will receive venetoclax in combination with ibrutinib for a total of 12 cycles, beginning at Cycle 4. For the first 5 weeks of venetoclax treatment, the treatment dose will be ramped up from 20 to 400 mg.
Participants will receive chlorambucil at a dose of 0.5 mg/kg body weight on Days 1 and 15 of Cycles 1 to 6.
Participant will receive obinutuzumab 1000 mg intravenously on Days 1, 8, and 15 of Cycle 1, and Day 1 of Cycles 2 to 6.
Participants will receive ibrutinib 420 mg orally once daily until disease progression or unacceptable toxicity during the subsequent therapy phase.
Progression Free Survival (PFS)
PFS: time between date of randomization and date of disease progression, as assessed by IRC, or date of death due to any cause, whichever occurs first, regardless of use of subsequent anti-cancer therapy prior to PD or death using iWCLL2008 criteria : New enlarged lymph nodes \>15 mm, new hepatomegaly or splenomegaly, or other organ infiltrates, bone lesion, ascites or pleural effusion due to CLL; \>=50% increase in longest diameter (LDi) from nadir in existing lymph node (LDi \>15 mm) or \>=50% increase from nadir in sum of diameters of multiple nodes (and at least 1 node with LDi \>15 mm); \>=50% increase from nadir in enlargement of liver/spleen; \>=50% increase from baseline in lymphocyte count (ALC; to \>=5\*10\^9/L); or \>=50% increase from nadir in ALC in \>=2 serial assessments if ALC is \>=30000\*10\^9/L and lymphocyte doubling time is rapid unless considered treatment-related lymphocytosis; new cytopenia attributable to CLL; transformation to more aggressive histology.
Time frame: Up to 2 years 10 months
Minimal Residual Disease (MRD) Negative Rate
MRD-negative rate is defined as the percentage of participants who achieved MRD-negative status (that is, less than \[\<\] 1 chronic lymphocytic leukemia (CLL) cell per 10,000 leukocytes or \<0.01 percentage \[%\]) in the bone marrow as assessed by next-generation sequencing (NGS). Participants with missing MRD data were considered MRD positive.
Time frame: Up to 2 years 10 months
Complete Response Rate (CRR)
Complete response rate is defined as the percentage of participants who achieved complete response or complete response with an incomplete marrow recovery (CRi) on or prior to initiation of subsequent anti-leukemic therapy per the IRC assessment. International Workshop on Chronic Lymphocytic Leukemia (iWCLL) 2008 criteria: CR- No lymphadenopathy and hepatosplenomegaly, no constitutional symptoms, neutrophils \>1.5\*10\^9/liter (L), platelets \>100\*10\^9/L, Hgb \>11 gram per deciliter (g/dL), absolute lymphocyte count \<4000/microliter (mcL) and normocellular bone marrow with \<30% lymphocytes and no B lymphoid nodules; CRi- CR with incomplete recovery of bone marrow.
Time frame: Up to 2 years 10 months
Overall Response Rate (ORR)
ORR: percentage of participants who achieved best overall response of either CR, CRi, nodular PR (nPR) and partial response (PR). iWCLL 2008 criteria: CR- No lymphadenopathy and hepatosplenomegaly, no constitutional symptoms, neutrophils \>1.5\*10\^9/liter (L), platelets \>100\*10\^9/L, Hgb \>11 g/dL and ALC \<4000/mcL, normocellular bone marrow with \<30% lymphocytes and no B lymphoid nodules; CRi- CR with incomplete recovery of bone marrow; nPR- participants meet criteria for CR, but bone marrow biopsy shows B-lymphoid nodules (reflecting residual disease); PR-2 of following when abnormal at baseline: \>=50% decrease in ALC, \>=50% decrease in sum of products of multiple nodes, \>=50% decrease in enlargement of spleen or liver; and 1 of following: neutrophils \>1.5\*10\^9/L, Platelets \>100\*10\^9/L and Hgb\>11 g/dL or \>=50% improvement over baseline in any of these; 50% reduction in bone marrow infiltrates or B lymphoid nodules; no new enlarged nodes or new hepatosplenomegaly.
Time frame: Up to 2 years 10 months
Overall Survival (OS)
OS is defined as the time from date of randomization to date of death from any cause.
Time frame: Up to 4 years 10 months
Duration of Response (DOR)
DOR is defined as the interval between the date of initial documentation of a response including partial response with lymphocytosis (PRL) and the date of first documented evidence of PD or death or date of censoring per the IRC assessment. iWCLL 2008 criteria for PD: New enlarged nodes \>1.5 cm, new hepatomegaly or splenomegaly, or other organ infiltrates; \>= 50% increase from nadir in existing lymph node or \>=50% increase from nadir in sum of product of diameters of multiple nodes; \>=50% increase from nadir in enlargement of liver or spleen; \>=50% increase from baseline in lymphocyte count (and to \>=5\*10\^9/L) unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b or platelets) attributable to CLL; transformation to a more aggressive histology.
Time frame: Up to 2 years 10 months
Time-to-Next Treatment
Time-to-next treatment was measured from the date of randomization to the start date of any subsequent anti-leukemic therapy.
Time frame: Up to 2 years 10 months
Time to Worsening as Measured by Using EuroQol 5 Dimension 5 Level Questionnaire (EQ-5D-5L)
Time to worsening= time interval (months) from randomization to first observation of deterioration. EQ-5D-5L consists of a 5-item descriptive system and the EuroQol visual analog scale (EQ-5D VAS). EQ-5D-VAS self-rating records respondent's own assessment of his/her overall health status at time of completion, on scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Worsening is defined as a decrease of \>= 7 points (on a 0-100 scale). EQ-5D-5L descriptive system comprises 5 dimensions of health (mobility, self -care, usual activities, pain/discomfort, and anxiety/depression) to describe participant's current health state. Responses for 5 dimensions are combined into a 5-digit number describing respondents health state that can be converted into a single index value or utility score (using the United Kingdom weights), ranging from -1 to 1, where lower scores indicate a worse health status. Worsening is defined as a decrease of \>=0.08 points (on a 0-1 scale).
Time frame: Up to 2 years 10 months
Time to Worsening Measured by European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire (EORTC QLQ)-C30)
Time to worsening= time interval from randomization to first observation of deterioration. EORTC QLQ-C30 includes 30 separate items: 5 functional scales (physical, role, emotional, cognitive, and social Functioning), 1 global health status (GHS) and QoL scale, 3 symptom scales (fatigue, nausea/vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Each item, except GHS, is answered on 4-point scale (1=not at all to 4=very much) and GHS is measured on 1-7 scale: 1=very poor and 7=excellent. Scores derived using validated scoring algorithms as per EORTC QLQ-C30 Manual and linearly transformed in a range from 0-100. For functional and global QoL scales, higher scores=better level of functioning/QoL. For symptom-oriented scales, higher score=more severe symptoms. Worsening in functional and global health scores=decrease of \>=10 points (on 0-100 scale) and in symptom scores=increase of \>=10 points (on 0-100 scale).
Time frame: Up to 2 years 10 months
Time to Worsening and Time to Improvement as Measured by Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Total Score
Responses to the 13-item FACIT Fatigue Scale are reported on a 5-point categorical response scale ranging from 0 (not at all) to 4 (very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score). Time to Worsening is defined as time interval (months) from randomization to first observation of deterioration. Worsening is defined as a decrease \>= 3 points (on a 0-52 scale). Time to improvement is defined as the time interval (months) from randomization to the first observation of improvement. Improvement is defined as an increase \>=3 points (on a 0-52 scale).
Time frame: Up to 2 years 10 months
Number of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability
An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.
Time frame: Up to 4 years 10 months
Number of Participants With Abnormal Clinical Laboratory Findings
Number of participants with abnormal clinical laboratory findings (hematology and serum chemistry) were reported.
Time frame: Up to 4 years 10 months
Percentage of Participants With Sustained Hemoglobin Improvement
Sustained hemoglobin improvement is defined as the percentage of participants who achieved an increase in hemoglobin levels from baseline by \>= 2 grams per deciliter (g/dL) and lasts for at least 56 days without blood transfusion or growth factors.
Time frame: Up to 2 years 10 months
Percentage of Participants With Sustained Platelet Improvement
Sustained platelet improvement is defined as the percentage of participants who achieved an increase in platelet levels from baseline by \>= 50% and lasts for at least 56 days without blood transfusion or growth factors.
Time frame: Up to 2 years 10 months
Plasma Concentration of Ibrutinib and Venetoclax
Plasma concentrations of ibrutinib and venetoclax were determined by validated liquid chromatography-tandem mass spectrometry.
Time frame: Ibrutinib: Pre-dose-Day 1 of Cycles 2, 3, 5 and 6 (each cycle is defined as 28 days), Venetoclax: Pre-dose-Day 1 of Cycles 5 and 6
| Milestone | Treatment Arm A (Ibrutinib + Venetoclax) | Treatment Arm B (Chlorambucil + Obinutuzumab) |
|---|---|---|
| Started | 106 | 105 |
| Completed | 15 | 30 |
| Not completed | 91 | 75 |
| Withdrew: Withdrawal by subject | 4 | 3 |
| Withdrew: Ongoing | 87 | 72 |
PFS: time between date of randomization and date of disease progression, as assessed by IRC, or date of death due to any cause, whichever occurs first, regardless of use of subsequent anti-cancer therapy prior to PD or death using iWCLL2008 criteria : New enlarged lymph nodes \>15 mm, new hepatomegaly or splenomegaly, or other organ infiltrates, bone lesion, ascites or pleural effusion due to CLL; \>=50% increase in longest diameter (LDi) from nadir in existing lymph node (LDi \>15 mm) or \>=50% increase from nadir in sum of diameters of multiple nodes (and at least 1 node with LDi \>15 mm); \>=50% increase from nadir in enlargement of liver/spleen; \>=50% increase from baseline in lymphocyte count (ALC; to \>=5\*10\^9/L); or \>=50% increase from nadir in ALC in \>=2 serial assessments if ALC is \>=30000\*10\^9/L and lymphocyte doubling time is rapid unless considered treatment-related lymphocytosis; new cytopenia attributable to CLL; transformation to more aggressive histology.
| Months | Treatment Arm A (Ibrutinib + Venetoclax) | Treatment Arm B (Chlorambucil + Obinutuzumab) |
|---|---|---|
| Progression Free Survival (PFS) | NA (31.24 to NA) | 20.96 (16.59 to 24.67) |
MRD-negative rate is defined as the percentage of participants who achieved MRD-negative status (that is, less than \[\<\] 1 chronic lymphocytic leukemia (CLL) cell per 10,000 leukocytes or \<0.01 percentage \[%\]) in the bone marrow as assessed by next-generation sequencing (NGS). Participants with missing MRD data were considered MRD positive.
| Percentage of participants | Treatment Arm A (Ibrutinib + Venetoclax) | Treatment Arm B (Chlorambucil + Obinutuzumab) |
|---|---|---|
| Minimal Residual Disease (MRD) Negative Rate | 55.7 (46.2 to 65.1) | 21.0 (13.2 to 28.7) |
Complete response rate is defined as the percentage of participants who achieved complete response or complete response with an incomplete marrow recovery (CRi) on or prior to initiation of subsequent anti-leukemic therapy per the IRC assessment. International Workshop on Chronic Lymphocytic Leukemia (iWCLL) 2008 criteria: CR- No lymphadenopathy and hepatosplenomegaly, no constitutional symptoms, neutrophils \>1.5\*10\^9/liter (L), platelets \>100\*10\^9/L, Hgb \>11 gram per deciliter (g/dL), absolute lymphocyte count \<4000/microliter (mcL) and normocellular bone marrow with \<30% lymphocytes and no B lymphoid nodules; CRi- CR with incomplete recovery of bone marrow.
| Percentage of Participants | Treatment Arm A (Ibrutinib + Venetoclax) | Treatment Arm B (Chlorambucil + Obinutuzumab) |
|---|---|---|
| Complete Response Rate (CRR) | 38.7 (29.4 to 48.0) | 11.4 (5.3 to 17.5) |
ORR: percentage of participants who achieved best overall response of either CR, CRi, nodular PR (nPR) and partial response (PR). iWCLL 2008 criteria: CR- No lymphadenopathy and hepatosplenomegaly, no constitutional symptoms, neutrophils \>1.5\*10\^9/liter (L), platelets \>100\*10\^9/L, Hgb \>11 g/dL and ALC \<4000/mcL, normocellular bone marrow with \<30% lymphocytes and no B lymphoid nodules; CRi- CR with incomplete recovery of bone marrow; nPR- participants meet criteria for CR, but bone marrow biopsy shows B-lymphoid nodules (reflecting residual disease); PR-2 of following when abnormal at baseline: \>=50% decrease in ALC, \>=50% decrease in sum of products of multiple nodes, \>=50% decrease in enlargement of spleen or liver; and 1 of following: neutrophils \>1.5\*10\^9/L, Platelets \>100\*10\^9/L and Hgb\>11 g/dL or \>=50% improvement over baseline in any of these; 50% reduction in bone marrow infiltrates or B lymphoid nodules; no new enlarged nodes or new hepatosplenomegaly.
| Percentage of participants | Treatment Arm A (Ibrutinib + Venetoclax) | Treatment Arm B (Chlorambucil + Obinutuzumab) |
|---|---|---|
| Overall Response Rate (ORR) | 86.8 (80.3 to 93.2) | 84.8 (77.9 to 91.6) |
OS is defined as the time from date of randomization to date of death from any cause.
| Months | Treatment Arm A (Ibrutinib + Venetoclax) | Treatment Arm B (Chlorambucil + Obinutuzumab) |
|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) |
DOR is defined as the interval between the date of initial documentation of a response including partial response with lymphocytosis (PRL) and the date of first documented evidence of PD or death or date of censoring per the IRC assessment. iWCLL 2008 criteria for PD: New enlarged nodes \>1.5 cm, new hepatomegaly or splenomegaly, or other organ infiltrates; \>= 50% increase from nadir in existing lymph node or \>=50% increase from nadir in sum of product of diameters of multiple nodes; \>=50% increase from nadir in enlargement of liver or spleen; \>=50% increase from baseline in lymphocyte count (and to \>=5\*10\^9/L) unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b or platelets) attributable to CLL; transformation to a more aggressive histology.
| Months | Treatment Arm A (Ibrutinib + Venetoclax) | Treatment Arm B (Chlorambucil + Obinutuzumab) |
|---|---|---|
| Duration of Response (DOR) | 28.85 (28.68 to NA) | 21.13 (15.93 to 25.10) |
Time-to-next treatment was measured from the date of randomization to the start date of any subsequent anti-leukemic therapy.
| Months | Treatment Arm A (Ibrutinib + Venetoclax) | Treatment Arm B (Chlorambucil + Obinutuzumab) |
|---|---|---|
| Time-to-Next Treatment | NA (NA to NA) | NA (31.54 to NA) |
Time to worsening= time interval (months) from randomization to first observation of deterioration. EQ-5D-5L consists of a 5-item descriptive system and the EuroQol visual analog scale (EQ-5D VAS). EQ-5D-VAS self-rating records respondent's own assessment of his/her overall health status at time of completion, on scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Worsening is defined as a decrease of \>= 7 points (on a 0-100 scale). EQ-5D-5L descriptive system comprises 5 dimensions of health (mobility, self -care, usual activities, pain/discomfort, and anxiety/depression) to describe participant's current health state. Responses for 5 dimensions are combined into a 5-digit number describing respondents health state that can be converted into a single index value or utility score (using the United Kingdom weights), ranging from -1 to 1, where lower scores indicate a worse health status. Worsening is defined as a decrease of \>=0.08 points (on a 0-1 scale).
| Months | Treatment Arm A (Ibrutinib + Venetoclax) | Treatment Arm B (Chlorambucil + Obinutuzumab) |
|---|---|---|
| EQ-5D-5L: Visual Analogue Score | 8.34 (5.65 to NA) | 24.18 (11.27 to NA) |
| EQ-5D-5L: Utility Score | 14.29 (8.15 to NA) | 24.11 (8.34 to NA) |
Time to worsening= time interval from randomization to first observation of deterioration. EORTC QLQ-C30 includes 30 separate items: 5 functional scales (physical, role, emotional, cognitive, and social Functioning), 1 global health status (GHS) and QoL scale, 3 symptom scales (fatigue, nausea/vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Each item, except GHS, is answered on 4-point scale (1=not at all to 4=very much) and GHS is measured on 1-7 scale: 1=very poor and 7=excellent. Scores derived using validated scoring algorithms as per EORTC QLQ-C30 Manual and linearly transformed in a range from 0-100. For functional and global QoL scales, higher scores=better level of functioning/QoL. For symptom-oriented scales, higher score=more severe symptoms. Worsening in functional and global health scores=decrease of \>=10 points (on 0-100 scale) and in symptom scores=increase of \>=10 points (on 0-100 scale).
| Months | Treatment Arm A (Ibrutinib + Venetoclax) | Treatment Arm B (Chlorambucil + Obinutuzumab) |
|---|---|---|
| Global Health Status | 14.95 (8.38 to NA) | 24.18 (13.86 to NA) |
| Cognitive Functioning | 11.07 (5.95 to 24.05) | 14.03 (7.16 to NA) |
| Emotional Functioning | NA (17.31 to NA) | 25.00 (16.62 to NA) |
| Physical Functioning | NA (19.42 to NA) | NA (14.03 to NA) |
| Role Functioning | 11.10 (6.28 to 14.95) | 8.48 (5.62 to 16.69) |
| Social Functioning | 11.10 (8.34 to 16.69) | 17.87 (11.07 to 25.30) |
| Fatigue (Symptom Scale) | 8.38 (5.62 to 14.95) | 17.87 (8.44 to NA) |
| Nausea/Vomiting (Symptom Scale) | 11.07 (8.28 to NA) | NA (20.44 to NA) |
| Pain (Symptom Scale) | 8.31 (5.45 to 13.90) | 11.01 (5.65 to 17.87) |
Responses to the 13-item FACIT Fatigue Scale are reported on a 5-point categorical response scale ranging from 0 (not at all) to 4 (very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score). Time to Worsening is defined as time interval (months) from randomization to first observation of deterioration. Worsening is defined as a decrease \>= 3 points (on a 0-52 scale). Time to improvement is defined as the time interval (months) from randomization to the first observation of improvement. Improvement is defined as an increase \>=3 points (on a 0-52 scale).
| Months | Treatment Arm A (Ibrutinib + Venetoclax) | Treatment Arm B (Chlorambucil + Obinutuzumab) |
|---|---|---|
| Time to Worsening | 8.15 (3.98 to 10.94) | 14.03 (8.61 to NA) |
| Time to Improvement | 5.59 (3.81 to 11.20) | 3.75 (2.20 to 5.75) |
An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.
| Participants | Treatment Arm A (Ibrutinib + Venetoclax) | Treatment Arm B (Chlorambucil + Obinutuzumab) |
|---|---|---|
| Number of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability | 105 | 99 |
Number of participants with abnormal clinical laboratory findings (hematology and serum chemistry) were reported.
| Participants | Treatment Arm A (Ibrutinib + Venetoclax) | Treatment Arm B (Chlorambucil + Obinutuzumab) |
|---|---|---|
| Hematology: Absolute Neutrophils Counts (Decrease) | 81 | 95 |
| Hematology: Hemoglobin (Decrease) | 38 | 42 |
| Hematology: Platelets (Decrease) | 52 | 78 |
| Hematology: Any hemoglobin, platelet, or ANC decrease | 94 | 103 |
| Chemistry: Alanine Transaminase (ALT) (Increase) | 22 | 26 |
| Chemistry: Aspartate Aminotransferase (AST) (Increase) | 23 | 30 |
| Chemistry: Alkaline Phosphatase (Increase) | 19 | 21 |
| Chemistry: Bilirubin (Increase) | 36 | 25 |
| Chemistry: Creatinine (Increase) | 33 | 17 |
| Chemistry: Creatinine Clearance (Decrease) | 40 | 17 |
| Chemistry: Hypercalcemia | 13 | 3 |
| Chemistry: Hypoalbuminemia | 36 | 20 |
| Chemistry: Hypocalcemia | 27 | 30 |
| Chemistry: Phosphate (Decrease) | 16 | 6 |
| Chemistry: Potassium (Decrease) | 25 | 9 |
| Chemistry: Potassium (Increase) | 31 | 22 |
| Chemistry: Sodium (Decrease) | 25 | 26 |
| Chemistry: Sodium (Increase) | 12 | 8 |
| Chemistry: Uric Acid (Increase) | 37 | 19 |
Sustained hemoglobin improvement is defined as the percentage of participants who achieved an increase in hemoglobin levels from baseline by \>= 2 grams per deciliter (g/dL) and lasts for at least 56 days without blood transfusion or growth factors.
| Percentage of Participants | Treatment Arm A (Ibrutinib + Venetoclax) | Treatment Arm B (Chlorambucil + Obinutuzumab) |
|---|---|---|
| Percentage of Participants With Sustained Hemoglobin Improvement | 44.3 | 50.5 |
Sustained platelet improvement is defined as the percentage of participants who achieved an increase in platelet levels from baseline by \>= 50% and lasts for at least 56 days without blood transfusion or growth factors.
| Percentage of Participants | Treatment Arm A (Ibrutinib + Venetoclax) | Treatment Arm B (Chlorambucil + Obinutuzumab) |
|---|---|---|
| Percentage of Participants With Sustained Platelet Improvement | 24.5 | 29.5 |
Plasma concentrations of ibrutinib and venetoclax were determined by validated liquid chromatography-tandem mass spectrometry.
| Nanograms per milliliter (ng/mL) | Treatment Arm A (Ibrutinib + Venetoclax) |
|---|---|
| Ibrutinib: Pre-dose Day 1 Cycle 2 (Ibrutinib Alone) | 5.70 ± 5.58 |
| Ibrutinib: Pre-dose Day 1 Cycle 3 (Ibrutinib Alone) | 6.20 ± 7.78 |
| Ibrutinib: Pre-dose Day 1 Cycle 5 (Ibrutinib and Venetoclax) | 6.37 ± 6.71 |
| Ibrutinib: Pre-dose Day 1 Cycle 6 (Ibrutinib and Venetoclax) | 5.90 ± 6.74 |
| Venetoclax: Pre-dose Day 1 Cycle 5 (Ibrutinib + Venetoclax) | 1139 ± 959 |
| Venetoclax: Pre-dose Day 1 Cycle 6 (Ibrutinib + Venetoclax) | 1765 ± 1573 |
Collected over Up to 4 years 10 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Arm A (Ibrutinib + Venetoclax) | 17/106 (16%) | 49/106 (46.2%) | 98/106 (92.5%) |
| Treatment Arm B (Chlorambucil + Obinutuzumab) | 36/105 (34.3%) | 30/105 (28.6%) | 98/105 (93.3%) |
| Event | Treatment Arm A (Ibrutinib + Venetoclax) | Treatment Arm B (Chlorambucil + Obinutuzumab) |
|---|---|---|
| Atrial FibrillationCardiac disorders | 7/106 | 0/105 |
| PneumoniaInfections and infestations | 6/106 | 6/105 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 1/106 | 3/105 |
| Infusion Related ReactionInjury, poisoning and procedural complications | 0/106 | 3/105 |
| Tumour Lysis SyndromeMetabolism and nutrition disorders | 0/106 | 3/105 |
| AnaemiaBlood and lymphatic system disorders | 3/106 | 2/105 |
| Cardiac FailureCardiac disorders | 3/106 | 0/105 |
| DiarrhoeaGastrointestinal disorders | 3/106 | 1/105 |
| PyrexiaGeneral disorders | 1/106 | 2/105 |
| OverdoseInjury, poisoning and procedural complications | 0/106 | 2/105 |
| Event | Treatment Arm A (Ibrutinib + Venetoclax) | Treatment Arm B (Chlorambucil + Obinutuzumab) |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 36/106 | 56/105 |
| DiarrhoeaGastrointestinal disorders | 53/106 | 13/105 |
| ThrombocytopeniaBlood and lymphatic system disorders | 12/106 | 28/105 |
| Infusion Related ReactionInjury, poisoning and procedural complications | 0/106 | 28/105 |
| NauseaGastrointestinal disorders | 28/106 | 27/105 |
| AnaemiaBlood and lymphatic system disorders | 17/106 | 18/105 |
| PyrexiaGeneral disorders | 6/106 | 18/105 |
| Urinary Tract InfectionInfections and infestations | 17/106 | 4/105 |
| RashSkin and subcutaneous tissue disorders | 17/106 | 7/105 |
| FatigueGeneral disorders | 16/106 | 10/105 |
| Age, Continuous(years) | Treatment Arm A (Ibrutinib + Venetoclax) | Treatment Arm B (Chlorambucil + Obinutuzumab) | Total |
|---|---|---|---|
| Mean | 71 ± 8.02 | 72 ± 6.16 | 71.5 ± 7.01 |
| Sex: Female, Male(Participants) | Treatment Arm A (Ibrutinib + Venetoclax) | Treatment Arm B (Chlorambucil + Obinutuzumab) | Total |
|---|---|---|---|
| Female | 47 | 42 | 89 |
| Male | 59 | 63 | 122 |
| Ethnicity (NIH/OMB)(Participants) | Treatment Arm A (Ibrutinib + Venetoclax) | Treatment Arm B (Chlorambucil + Obinutuzumab) | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 3 | 4 |
| Not Hispanic or Latino | 101 | 99 | 200 |
| Unknown or Not Reported | 4 | 3 | 7 |
| Race (NIH/OMB)(Participants) | Treatment Arm A (Ibrutinib + Venetoclax) | Treatment Arm B (Chlorambucil + Obinutuzumab) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 101 | 101 | 202 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 4 | 3 | 7 |
| Region of Enrollment(Participants) | Treatment Arm A (Ibrutinib + Venetoclax) | Treatment Arm B (Chlorambucil + Obinutuzumab) | Total |
|---|---|---|---|
| BELGIUM | 7 | 2 | 9 |
| CANADA | 7 | 10 | 17 |
| CZECH REPUBLIC | 9 | 13 | 22 |
| DENMARK | 7 | 5 | 12 |
| FRANCE | 4 | 3 | 7 |
| ISRAEL | 6 | 12 | 18 |
| NETHERLANDS | 1 | 6 | 7 |
| POLAND | 12 | 10 | 22 |
| RUSSIAN FEDERATION | 23 | 16 | 39 |
| SPAIN | 10 | 9 | 19 |
| SWEDEN | 2 | 0 | 2 |
| TURKEY | 8 | 13 | 21 |
| UNITED KINGDOM | 8 | 4 | 12 |
| UNITED STATES | 2 | 2 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2018 to primary completion in Feb 2021, 34 months.
Results were first posted in Mar 2022, 1 year 1 month after primary completion.
Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 34 months is below that.
Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ibrutinib · Venetoclax
Leukemia, Lymphocytic, Chronic, B-Cell →
Janssen Research & Development, LLC →